在心力衰竭中准LUM介导的炎症细胞通信和纤维细胞亡与SFI
Tiansheng Su1, Tingyu Luo1, Yu Lin1
1Department of Emergency, The Second Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, 350003, China.
SLAS technology
|February 1, 2026
概括
沈福注射 (SFI) 通过向炎症和亡的关键基因Lumican (LUM) 来缓解心力衰竭 (HF). 通过调节这一关键细胞通信通路,SFI可减少心脏损伤并改善心脏功能.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 心力衰竭 (HF) 是导致死亡的首要原因,由炎症和中断的细胞间通信驱动.
- 传统中医药的精确分子机制,比如神福注射 (SFI),在治疗高血压时还没有完全理解.
研究的目的:
- 为了研究心力衰竭微环境中的细胞和分子变化.
- 阐明神福注射 (SFI) 在心力衰竭中的治疗机制.
- 确定HF的新型治疗点.
主要方法:
- 集成的单细胞RNA测序 (scRNA-seq),批量转录组学和机器学习.
- 分析了细胞与细胞之间的相互作用和信号通路.
- 在心力衰竭的小鼠模型中验证了SFI效应.
主要成果:
- 高血压表现出一种亲炎性心脏微环境,免疫细胞激活和亡的增加,特别是在纤维细胞中.
- Lumican (LUM) 被确定为纤维细胞特异性,与亡相关的枢纽基因,是HF病理学的核心.
- SFI治疗降低了LUM和p38/p53通路的调节,减少了炎症,心肌细胞亡,并改善了心脏功能.
结论:
- 卢米坎 (LUM) 是关键的调节器,在心力衰竭中将亡,炎症和细胞间通信联系起来.
- 沈福注射 (SFI) 通过准LUM介导的信号轴,产生心脏保护作用.
- 以LUM为中心的炎症传播网络代表了心力衰竭的潜在治疗目标.
相关概念视频
01:29Heart Failure II: Pathophysiology
929
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
01:17Pathophysiology of Heart Failure
3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
01:27Heart Failure I: Introduction
886
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
01:22Heart Failure VI: Adjunct Therapies
340
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
01:22Heart Failure Drugs: Diuretics
971
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971
01:30Heart Failure V: Medical Management
319
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
319